prasinezumab

Prasinezumab

Prasinezumab (also known as RO7046015/PRX002) is an experimental humanized monoclonal antibody therapy designed to target and clear alpha-synuclein protein aggregates, which are the hallmark pathological features of Parkinson's disease and related synucleinopathies[@bridi2022]. Developed by Prothena Biosciences in partnership with Roche, this immunotherapy represents one of the most advanced disease-modifying approaches targeting the alpha-synuclein pathological pathway[@brundin2022].

Overview

Prasinezumab is a humanized IgG1 monoclonal antibody that binds to the C-terminus of alpha-synuclein, with particular affinity for aggregated forms of the protein rather than monomeric species[@lang2019]. This selective binding profile is critical because it allows the antibody to target the pathological species while sparing the normal physiological function of monomeric alpha-synuclein in synaptic vesicle trafficking and dopamine synthesis.

The therapeutic rationale for prasinezumab rests on the central role of alpha-synuclein aggregation in Parkinson's disease pathogenesis. By binding to extracellular and circulating alpha-synuclein aggregates, prasinezumab aims to:

Clear pathological aggregates through Fc receptor-mediated uptake by microglia

Inhibit seeding of endogenous alpha-synuclein by neutralizing extracellular aggregates

Create a peripheral sink that draws toxic species from the CNS to the periphery

...

Prasinezumab

Prasinezumab (also known as RO7046015/PRX002) is an experimental humanized monoclonal antibody therapy designed to target and clear alpha-synuclein protein aggregates, which are the hallmark pathological features of Parkinson's disease and related synucleinopathies[@bridi2022]. Developed by Prothena Biosciences in partnership with Roche, this immunotherapy represents one of the most advanced disease-modifying approaches targeting the alpha-synuclein pathological pathway[@brundin2022].

Overview

Prasinezumab is a humanized IgG1 monoclonal antibody that binds to the C-terminus of alpha-synuclein, with particular affinity for aggregated forms of the protein rather than monomeric species[@lang2019]. This selective binding profile is critical because it allows the antibody to target the pathological species while sparing the normal physiological function of monomeric alpha-synuclein in synaptic vesicle trafficking and dopamine synthesis.

The therapeutic rationale for prasinezumab rests on the central role of alpha-synuclein aggregation in Parkinson's disease pathogenesis. By binding to extracellular and circulating alpha-synuclein aggregates, prasinezumab aims to:

Clear pathological aggregates through Fc receptor-mediated uptake by microglia

Inhibit seeding of endogenous alpha-synuclein by neutralizing extracellular aggregates

Create a peripheral sink that draws toxic species from the CNS to the periphery

This multi-faceted approach addresses both the symptoms (by reducing toxic species) and the cause (by potentially slowing or halting disease progression)[@pagano2021].

Mechanism of Action

Antibody Binding Profile

Prasinezumab binds to a conformational epitope in the C-terminal region of alpha-synuclein (residues 109-132), which becomes more accessible upon protein aggregation[@gao2020]. The antibody shows significantly higher affinity for:

• Oligomeric alpha-synuclein: Soluble aggregates that are considered highly toxic
• Fibrillar alpha-synuclein: Mature fibrils that compose Lewy bodies
• Membrane-bound alpha-synuclein: Species associated with synaptic dysfunction

The binding to monomeric alpha-synuclein is relatively weak, which is advantageous as it allows the antibody to spare the normal physiological function of monomeric protein in synaptic vesicle trafficking[@masucci2019].

Fc Receptor-Mediated Clearance

Once bound to alpha-synuclein aggregates, prasinezumab engages the Fc gamma receptor (FcγR) on microglia and other immune cells, triggering receptor-mediated phagocytosis and lysosomal degradation of the targeted species[@zella2020]:

This Fc-dependent mechanism is critical for the therapeutic effect, as it enables active clearance of pathological species that would otherwise accumulate in the brain.

Seeding Inhibition

Alpha-synuclein pathology spreads through a prion-like mechanism, where pathological species act as templates for the misfolding of endogenous protein. By neutralizing extracellular aggregates, prasinezumab may prevent this template-mediated propagation[@bridi2022]:

• Neutralization of extracellular seeds: Antibody binding inactivates seeding-competent species
• Prevention of neuron-to-neuron spread: Blocking the propagation between cells
• Interruption of templated misfolding: Reducing the conversion of endogenous protein

Peripheral Sink Effect

The antibody creates a concentration gradient that favors movement of alpha-synuclein from the CNS to the periphery[@pagano2021]:

• Serum antibody binding: Creates a sink in the bloodstream
• Blood-brain barrier gradient: Promotes efflux of CNS alpha-synuclein
• Enhanced peripheral clearance: Liver and spleen contribute to elimination

Clinical Development

Phase 1 Trials

Phase 1 clinical trials (NCT02095171 and NCT02645621) established the safety and pharmacokinetics of prasinezumab in both healthy volunteers and Parkinson's disease patients[@jensen2019][@bergstrom2021]:

Key Findings:

• Safety: Prasinezumab was safe and well-tolerated at all doses tested
• Pharmacokinetics: Dose-linear exposure with half-life supporting monthly dosing
• Target engagement: Significant reduction in free serum alpha-synuclein (up to 97% reduction)
• Immunogenicity: Low incidence of anti-drug antibodies

Dosing Regimen:

• Single ascending doses from 0.3 mg/kg to 10 mg/kg
• Multiple ascending doses over 12 weeks
• Monthly maintenance dosing in extension studies

Phase 2 Trial (PASADENA)

The PASADENA trial (NCT03100149) was a randomized, double-blind, placebo-controlled Phase 2 study evaluating prasinezumab in patients with early-stage Parkinson's disease[@pagano2021]:

Study Design:

• 316 patients enrolled
• Early-stage PD (MDS-UPDRS Parts II+III ≤30)
• Treatment for 52 weeks
• Primary endpoint: Change in MDS-UPDRS total score

Results:
While the trial did not meet its primary endpoint (no statistically significant difference in MDS-UPDRS change), pre-specified analyses revealed potential disease-modifying effects:

• Motor progression: Slower progression in patients receiving higher doses (6 mg/kg)
• Dopaminergic protection: Reduced decline in dopamine transporter binding on SPECT imaging (DAT-scan)
• Motor complications: Fewer dyskinesias and motor fluctuations in treatment groups

Post-hoc Analyses:
Subsequent analyses identified subgroups that appeared to benefit more from treatment:

• Patients with faster progression at baseline
• Patients with more severe dopaminergic deficit
• Patients with specific biomarker profiles

Open-Label Extension (OLE)

The open-label extension of PASADENA is ongoing to evaluate long-term safety and efficacy[@johnson2024]:

• Duration: Up to 3 years of continuous treatment
• Design: All patients receive active treatment (blinded dose)
• Endpoints: Long-term safety, motor progression, cognitive decline

Phase 2b Trial (PADOVA)

The PADOVA trial (NCT04700131) is a Phase 2b study specifically designed to address the lessons learned from PASADENA[@volc2024]:

Key Design Features:

• Patient selection: Enrolling patients with faster progression phenotype
• Higher dosing: Exploring doses up to 15 mg/kg
• Biomarker enrichment: Using CSF alpha-synuclein seeding assay for selection
• Longer duration: 72-week treatment period

Rationale:
The Phase 2b design incorporates learnings from PASADENA, specifically targeting patients most likely to show measurable benefit from alpha-synuclein immunotherapy.

Biomarker Research

Biomarker development is critical for patient selection and treatment response monitoring in prasinezumab trials[@weiss2024]:

Cerebrospinal Fluid Biomarkers

Alpha-synuclein seeding assays:

• RT-QuIC (Real-Time Quaking-Induced Conversion)
• PMCA (Protein Misfolding Cyclic Amplification)
• Distinguish pathological from physiological alpha-synuclein

Other CSF markers:

• Neurofilament light chain (NfL): Marker of neuroaxonal injury
• Total tau: Marker of neurodegeneration
• Beta-amyloid and tau: For differential diagnosis

Blood Biomarkers

Neurofilament light chain (NfL):

• Elevated in Parkinson's disease
• Correlates with disease progression
• May predict treatment response

Plasma exosomal alpha-synuclein:

• Neuronally-derived exosomes contain alpha-synuclein
• Potential for disease monitoring
• Emerging biomarker

Neuroimaging Biomarkers

Dopamine transporter imaging (DAT-scan):

• Measures presynaptic dopaminergic integrity
• Reduced decline in prasinezumab-treated patients
• Proxy for disease modification

Other imaging:

• Structural MRI: Brain volume changes
• PET: Alpha-synuclein burden (in development)
• Functional imaging: Network connectivity

Clinical Significance

Prasinezumab represents one of the most advanced alpha-synuclein-targeting immunotherapies in development and carries significant clinical implications for Parkinson's disease treatment[@brundin2022]:

Disease Modification vs. Symptomatic Treatment

Unlike dopaminergic medications that temporarily improve symptoms, prasinezumab aims to modify the underlying disease process:

• Symptomatic treatments: Dopamine agonists, MAO-B inhibitors, levodopa
• Disease-modifying approaches: Alpha-synuclein immunotherapy, gene therapy, cell replacement

The distinction is critical because current symptomatic treatments do not slow disease progression, and patients inevitably develop complications including motor fluctuations and dyskinesias.

Therapeutic Target Validation

The prasinezumab program provides important validation of the alpha-synuclein hypothesis:

• Genetic evidence: SNCA mutations cause familial PD
• Pathological evidence: Lewy bodies define the disease
• Therapeutic evidence: Does immunotherapy improve outcomes?

Positive results would strongly validate alpha-synuclein as a therapeutic target.

Patient Subgroup Identification

The trials have identified factors that may predict treatment response[@smith2021]:

• Disease stage: Earlier intervention may be more effective
• Progression rate: Faster progressors may show more benefit
• Biomarker status: Pathological alpha-synuclein burden matters
• Genetic factors: GBA carrier status, SNCA variants

Comparison to Other Alpha-Synuclein Approaches

Prasinezumab is one of several alpha-synuclein-targeting immunotherapies in development:

| Therapy | Company | Target | Status | Notes |
|---------|---------|--------|--------|-------|
| Prasinezumab (RO7046015) | Prothena/Roche | α-synuclein | Phase 2b | Most advanced |
| Cinpanemab (BIIB054) | Biogen | α-synuclein | Phase 2 (discontinued) | No clear efficacy |
| ABBV-951 | AbbVie | α-synuclein | Phase 1 | Novel epitope |
| UCABS-1 | UCB Pharma | α-synuclein | Preclinical | Small molecule |
| Buntanetap | Junshi Biosciences | α-synuclein translation | Phase 3 | Oral small molecule |

Active vs. Passive Immunization

Passive immunization (prasinezumab):

• Administered monoclonal antibody
• Immediate effect
• Regular infusions required
• Well-characterized dosing

Active immunization (e.g., Affitope PD01):

• Vaccine induces endogenous antibody production
• Longer-lasting effect
• Variable individual response
• Lower cost potential

Mechanism in Neurodegeneration

Alpha-Synuclein Pathology

In Parkinson's disease, alpha-synuclein misfolds and aggregates through a well-characterized pathway:

Monomeric alpha-synuclein: Normally unfolded protein

Oligomerization: Formation of soluble toxic intermediates

Fibrillization: Assembly into amyloid fibrils

Lewy body formation: Deposition of fibrils in inclusions

Neuronal dysfunction: Multiple toxic mechanisms

Prasinezumab aims to intercept these pathological species before they cause irreversible neuronal damage.

Neuroinflammation

Alpha-synuclein aggregates activate microglia through multiple pathways[@gao2020]:

• TLR2/TLR4 recognition: Pattern recognition receptors detect aggregates
• NLRP3 inflammasome: Intracellular inflammatory activation
• Cytokine release: IL-1β, TNF-α, IL-6
• Chronic activation: Self-perpetuating neuroinflammation

By reducing extracellular alpha-synuclein, prasinezumab may dampen microglial activation and break the inflammatory cycle.

Synaptic Dysfunction

Alpha-synuclein oligomers disrupt synaptic function:

• Vesicle trafficking: Impairs neurotransmitter release
• Calcium homeostasis: Alters calcium signaling
• Synaptic protein interactions: Disrupts normal protein networks
• Synaptic loss: Precedes neuronal death

Prasinezumab may prevent these early dysfunctions before they progress to neuronal loss.

Side Effects and Safety Profile

In clinical trials, prasinezumab has generally been well-tolerated with a favorable safety profile:

Common Adverse Events

| Adverse Event | Frequency | Severity |
|---------------|-----------|----------|
| Infusion-related reactions | 10-15% | Mild to moderate |
| Headache | 8-12% | Mild |
| Fatigue | 7-10% | Mild |
| Nausea | 5-8% | Mild |
| Back pain | 5-7% | Mild |

Laboratory Abnormalities

• Mild increases in liver enzymes: Transitory, not clinically significant
• No hematologic toxicity: Safe across all doses
• No renal toxicity: No signal in renal function markers

Serious Adverse Events

Serious adverse events have been rare and not clearly related to study drug:

• Single cases of serious infusion reactions (managed with standard protocols)
• No increase in infections despite immunomodulatory mechanism
• No autoimmune phenomena observed

Immunogenicity

• Anti-drug antibodies: Low incidence (<5%)
• Neutralizing antibodies: Rare
• No impact on pharmacokinetics or efficacy

Future Directions

Ongoing research aims to maximize the therapeutic potential of alpha-synuclein immunotherapy:

Patient Selection

• Biomarker-driven selection: Using alpha-synuclein seeding assays
• Genetic stratification: Identifying optimal responders
• Disease stage optimization: Earlier intervention studies

Combination Approaches

Combining alpha-synuclein immunotherapy with other approaches may enhance efficacy[@lee2022]:

• Multiple antibodies: Targeting different epitopes
• Small molecules: Aggregation inhibitors plus immunotherapy
• Cell replacement: Combining with dopaminergic cell therapy
• Symptomatic drugs: Immunotherapy plus standard care

Disease Modification Endpoints

Developing robust measures of disease modification:

• Clinical endpoints: Motor progression, disability
• Biomarker endpoints: CSF, blood, imaging
• Digital biomarkers: Wearable sensors for continuous monitoring
• Composite endpoints: Multi-domain assessment

Pharmacological Properties

Antibody Structure

Prasinezumab is a humanized IgG1 monoclonal antibody:

• Variable region: Humanized from murine parent antibody
• Constant region: Human IgG1 framework
• Glycosylation: Standard Fc N-linked glycans
• Molecular weight: ~150 kDa

Pharmacokinetics

The pharmacokinetic profile supports monthly intravenous dosing[@bergstrom2021]:

• Half-life: ~21-28 days
• Volume of distribution: ~3-4 L (similar to plasma volume)
• Clearance: Low, supporting infrequent dosing
• CSF penetration: Limited (typical for large molecules)

Drug-Drug Interactions

No significant drug-drug interactions are expected:

• No effect on CYP enzymes
• No renal clearance
• Standard monoclonal antibody profile

Regulatory Status

Prasinezumab is currently in late-stage clinical development:

• FDA: Fast Track designation granted
• EMA: PRIME designation granted
• Timeline: Phase 2b results expected 2025-2026

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Alpha-Synuclein Aggregation](/mechanisms/alpha-synuclein-aggregation)
• [SNCA Gene](/genes/snca)
• [Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies)
• [Multiple System Atrophy](/diseases/multiple-system-atrophy)
• [Neuroinflammation](/mechanisms/neuroinflammation-neurodegeneration)

External Links

• [ClinicalTrials.gov - Prasinezumab](https://clinicaltrials.gov/search?cond=Parkinson%27s%20disease&intr=Prasinezumab)
• [Roche Pipeline](https://www.roche.com/research_and_development/pipeline/)
• [Michael J. Fox Foundation - Alpha-Synuclein](https://www.michaeljfox.org/research/)
• [Parkinson's Foundation - Treatment Developments](https://www.parkinson.org/)

Allen Brain Atlas Resources

• [Allen Human Brain Atlas](https://human.brain-map.org/) — Brain gene expression data for SNCA/alpha-synuclein
• [Allen Cell Type Atlas](https://celltypes.brain-map.org/) — Single-cell expression data for dopaminergic neurons